【摘要】 目的:观察纤溶酶的溶栓效果和安全性。方法:对符合入选条件的急性脑梗死患者按随机表进行分组,分别采用纤溶酶(治疗组)与尿激酶(对照组)进行一次性溶栓治疗,观察患者症状、体征的变化、不良反应以及电生理、CT、凝血功能、生化指标等变化,用《卒中患者临床神经功能缺失程度评分标准》评价临床疗效,并对各项观察指标进行统计学处理。结果:治疗组与对照组在治疗前后临床疗效评分、脑电图、心电图、血小板、凝血时间和D-二聚体、血糖、尿素氮和转氨酶等方面的变化,均无显著性差异,P>0.05(除于治疗后1d在纤维蛋白原方面P<0.05);而于溶栓治疗后1~7dCT显示,脑出血发生率治疗组为4.8%,与对照组26.3%比较有显著性差异,P<0.05。结论:纤溶酶治疗脑梗死临床疗效满意,并发脑出血机率低,值得推广应用。更多还原

【Abstract】 Objectives:To observe the effect and safety of intravenous plasmin in treatment of cases of acute cerebral infarction.Methods:Firstly we divided patients with acute cerebral infarction into two groups randomly,then gave single-dose treatment of intravenous plasmin(treatment group) and urokinase(control group).Lastly,weObserved the changes of symptoms,physical changes,adverse reactions,electrophysiology,CT,function of cruor,and standards of biochemistry.We evaluated the therapeutic effect according to The Standards of Evaluating the Loss of Neural Function on Stroke Patients,and did the statistical analysis.Results:There are not significant differences between the two groups in changes of clinical therapeutic effects,electroencephalogram,electrocardiogram,blood platelets,cruor time,D-dimer,blood sugar,urea nitrogen,and transaminase etc.pre-and after-treatment(P>0.05)(except of fibrinogen after one-day treatment,P<0.05).However,there are significant differences in occurrence of cerebral hemorrhage(the incidence rate for the treatment group was 4.8% and 26.3% for the control group,P<0.05) according to CT after 1～7 day treatment.Conclusions:The clinical therapeutic effects of treating cerebral infarction with plasmin are satisfying and there is little probability of intracerebral hemorrhage.Therefore the treatment is worth promoting.更多还原